[Transmembrane Na+ transport kinetics in arterial hypertension: relations with vascular risk parameters]. 1995

A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Sevilla.

BACKGROUND To characterize the possible existence of kinetic anomalies of four erythrocyte membrane sodium transport systems in a group of essential hypertensive patients, and to study the clinical and biochemical profile of those with anomalies. METHODS We studied 33 essential hypertensive patients and 33 normotensive controls. The kinetics (maximal rate and apparent dissociation constant for internal sodium) of Na(+)-K+ pump, Na(+)-K(+)-Cl- cotransport and Na(+)-Li+ countertransport was calculated after a sodium loading procedure, according to the methods of Garay; the passive Na+ permeability was also determined. RESULTS The studied kinetic parameters were not significantly different in both groups. Nevertheless, we found a group of hypertensive patients with some transport abnormalities: increased intracellular sodium (9.1%), accelerated Na+ passive permeability (9.1%), lower activity of the Na(+)-K+ pump (7.1%) and the Na(+)-K(+)-Cl- cotransport (4%) and an increased maximal rate of the Na(+)-Li+ countertransport (11.8%). Na+Li+ countertransport activity was statistically related to plasma levels of urea, creatinine, glucose and LDL-cholesterol, and the activity of the Na(+)-K(+)-Cl- cotransport was related to plasma uric acid. The hypertensive patients with sodium transport anomalies showed higher body mass index, uric acid plasma levels and atherogenic index than those without these kind of anomalies, and they also showed lowered HDL-cholesterol plasma levels. CONCLUSIONS A small group of essential hypertensive patients (around 31%) show kinetic alterations of sodium transport systems. There is a relation between Na(+)-Li+ countertransport activity and some cardiovascular risk parameters. Hypertensive patients with transport anomalies are a group with an increased cardiovascular risk.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004910 Erythrocyte Membrane The semi-permeable outer structure of a red blood cell. It is known as a red cell 'ghost' after HEMOLYSIS. Erythrocyte Ghost,Red Cell Cytoskeleton,Red Cell Ghost,Erythrocyte Cytoskeleton,Cytoskeleton, Erythrocyte,Cytoskeleton, Red Cell,Erythrocyte Cytoskeletons,Erythrocyte Ghosts,Erythrocyte Membranes,Ghost, Erythrocyte,Ghost, Red Cell,Membrane, Erythrocyte,Red Cell Cytoskeletons,Red Cell Ghosts
D005260 Female Females

Related Publications

A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
February 1988, Medicina clinica,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1984, Minerva cardioangiologica,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1997, Minerva medica,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1996, Medicina,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
March 1991, Diabetes care,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
March 1982, Minerva cardioangiologica,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1986, Annals of the New York Academy of Sciences,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1975, Annales de cardiologie et d'angeiologie,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1988, The American journal of medicine,
A Caballero Oliver, and P Stiefel García-Junco, and M A García-Donas López, and J Villar Ortiz, and J Carneado de la Fuente
January 1990, Revista espanola de cardiologia,
Copied contents to your clipboard!